PLUS1
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -166.00 | -1.54% | 10,644.00 | 10,660.00 | 10,662.00 | 10,874.00 | 10,654.00 | 10,784.00 | 2,307,484 | 16:35:21 |
| Industry Sector | Turnover (m) | Profit (m) | EPS - Basic | PE Ratio | Market Cap (m) |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 27,668.9 | -196.0 | 5.9 | 1,651.4 | 164,888 |
AstraZeneca Gets EU Approval for Ultomiris Drug
23/09/2022 7:42am
Dow Jones News
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jul 2022 to Jan 2023
By Sabela Ojea
AstraZeneca PLC said Friday that its Ultomiris drug has been approved in the European Union for the treatment of adults with the rare disease generalized myasthenia gravis.
The Anglo-Swedish pharma giant said that Ultomiris may reduce treatment burden with dosing every eight weeks, it said, adding that the drug also proved an improvement in activities of daily living.
Generalized myasthenia gravis is a rare autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness, AstraZeneca said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 23, 2022 02:27 ET (06:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |